305 related articles for article (PubMed ID: 27016922)
1. Sclerostin Inhibition in the Management of Osteoporosis.
Appelman-Dijkstra NM; Papapoulos SE
Calcif Tissue Int; 2016 Apr; 98(4):370-80. PubMed ID: 27016922
[TBL] [Abstract][Full Text] [Related]
2. Anti-sclerostin antibodies: utility in treatment of osteoporosis.
Clarke BL
Maturitas; 2014 Jul; 78(3):199-204. PubMed ID: 24842796
[TBL] [Abstract][Full Text] [Related]
3. Anti-sclerostin - is there an indication?
Larsson S
Injury; 2016 Jan; 47 Suppl 1():S31-5. PubMed ID: 26768288
[TBL] [Abstract][Full Text] [Related]
4. Biological agents in management of osteoporosis.
Tella SH; Gallagher JC
Eur J Clin Pharmacol; 2014 Nov; 70(11):1291-301. PubMed ID: 25204309
[TBL] [Abstract][Full Text] [Related]
5. Future directions for new medical entities in osteoporosis.
Ferrari S
Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357
[TBL] [Abstract][Full Text] [Related]
6. Romosozumab: from basic to clinical aspects.
Minisola S
Expert Opin Biol Ther; 2014 Sep; 14(9):1225-8. PubMed ID: 24835636
[TBL] [Abstract][Full Text] [Related]
7. Role of Wnt signaling and sclerostin in bone and as therapeutic targets in skeletal disorders.
Marini F; Giusti F; Palmini G; Brandi ML
Osteoporos Int; 2023 Feb; 34(2):213-238. PubMed ID: 35982318
[TBL] [Abstract][Full Text] [Related]
8. Targeted inhibition of sclerostin for post-menopausal osteoporosis therapy: A critical assessment of the mechanism of action.
Bhattacharyya S; Pal S; Chattopadhyay N
Eur J Pharmacol; 2018 May; 826():39-47. PubMed ID: 29476877
[TBL] [Abstract][Full Text] [Related]
9. Targeting Sclerostin in Postmenopausal Osteoporosis: Focus on Romosozumab and Blosozumab.
Reid IR
BioDrugs; 2017 Aug; 31(4):289-297. PubMed ID: 28547661
[TBL] [Abstract][Full Text] [Related]
10. Sclerostin and skeletal health.
Sharifi M; Ereifej L; Lewiecki EM
Rev Endocr Metab Disord; 2015 Jun; 16(2):149-56. PubMed ID: 25669441
[TBL] [Abstract][Full Text] [Related]
11. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.
Recker RR; Benson CT; Matsumoto T; Bolognese MA; Robins DA; Alam J; Chiang AY; Hu L; Krege JH; Sowa H; Mitlak BH; Myers SL
J Bone Miner Res; 2015 Feb; 30(2):216-24. PubMed ID: 25196993
[TBL] [Abstract][Full Text] [Related]
12. Romosozumab for the treatment of osteoporosis.
Bandeira L; Lewiecki EM; Bilezikian JP
Expert Opin Biol Ther; 2017 Feb; 17(2):255-263. PubMed ID: 28064540
[TBL] [Abstract][Full Text] [Related]
13. Update on romosozumab : a humanized monoclonal antibody to sclerostin.
Costa AG; Bilezikian JP; Lewiecki EM
Expert Opin Biol Ther; 2014 May; 14(5):697-707. PubMed ID: 24665957
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic innovation in osteoporosis (antisclerostin antibody and denosumab)].
Quemerais-Durieu MA; Kerlan V; Chabre O
Ann Endocrinol (Paris); 2011 Oct; 72 Suppl 1():S15-22. PubMed ID: 22008272
[TBL] [Abstract][Full Text] [Related]
15. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis].
Soen S
Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502
[TBL] [Abstract][Full Text] [Related]
16. Profile of romosozumab and its potential in the management of osteoporosis.
Lim SY; Bolster MB
Drug Des Devel Ther; 2017; 11():1221-1231. PubMed ID: 28458516
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin inhibition: a novel therapeutic approach in the treatment of osteoporosis.
Shah AD; Shoback D; Lewiecki EM
Int J Womens Health; 2015; 7():565-80. PubMed ID: 26082665
[TBL] [Abstract][Full Text] [Related]
18. Sclerostin: a novel target for intervention in the treatment of osteoporosis.
Lewiecki EM
Discov Med; 2011 Oct; 12(65):263-73. PubMed ID: 22031665
[TBL] [Abstract][Full Text] [Related]
19. Trial watch: Bone-building antibody outshines current treatments in osteoporosis trial.
Harrison C
Nat Rev Drug Discov; 2014 Apr; 13(4):248. PubMed ID: 24625823
[No Abstract] [Full Text] [Related]
20. Nonclinical cardiovascular safety evaluation of romosozumab, an inhibitor of sclerostin for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Turk JR; Deaton AM; Yin J; Stolina M; Felx M; Boyd G; Bienvenu JG; Varela A; Guillot M; Holdsworth G; Wolfreys A; Dwyer D; Kumar SV; de Koning EM; Qu Y; Engwall M; Locher K; Ward LD; Glaus C; He YD; Boyce RW
Regul Toxicol Pharmacol; 2020 Aug; 115():104697. PubMed ID: 32590049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
